LongevityBiz Deep Dive 13
By Rick Polito, LongevityBiz editor in chief
Thanks to an official FDA “enforcement discretion” declaration announced Oct. 28, US compounding pharmacies can now make a half-dozen synthetic peptides that had gained popularity with biohackers at the fringe of the longevity industry and were previously shipped without prescriptions to consumers as “for research only” drugs. Physicians, in turn, can prescribe them. Drugs that were used illegally until two weeks ago can now be carried through longevity clinic doors as tacitly legal drugs.
Whether injectable peptides actually make it past those doors, however, still depends on the clinic operator’s tolerance for risk.
Pharmaceuticals are regulated at the federal level. The practice of medicine is governed at the state level. From medical marijuana to abortion, the rules can vary radically. How states will confront the use of synthetic peptides like BPC-157, TB-500, and epitalon, the latter touted as a longevity solution, is far from clear.
Attorneys general often look for opportunities to grandstand for public health as a stepping stone to run for governor. With the enforcement declaration tightly tied to Robert F. Kennedy Jr., it’s easy to see an attorney general seizing maximum headlines in a political environment turned bright blue by last week’s midterms.
Malpractice insurance companies might also not share Kennedy’s fondness for peptides. Whether or not Kennedy wants to enforce the laws doesn’t change the fact that peptides are unapproved drugs. Psilocybin provides a parallel. It can be used legally in Oregon and Colorado, but it remains outlawed at the federal level, meaning insurers could deny malpractice coverage to doctors who prescribe or administer psychedelic drugs.
State medical boards would have no shortage of reasons to question how the peptides are employed in longevity care. While peptide advocates promote benefits and indications, the FDA’s own review board cited a lack of safety and efficacy evidence for the peptides and suggested that the FDA’s Pharmacy Compounding Advisory Committee not recommend allowing compounding pharmacies to make them. The committee, presently populated by Kennedy appointees, approved six of seven peptides being reviewed.
Justifications for that approval and the enforcement discretion include the reality that consumers are already accessing peptides online and that licensed production will make peptides safer. Clinics that choose to offer peptide therapy would do well to use the most reputable labs to test the peptides and seek guidance on how to review those labs.
“Wherever you're getting it from, go above and beyond to make sure it's of the highest quality and it passes all sorts of gates that you need to get through because these things are going into people's bodies,” says Ernie Rapp, chief business development officer at PCCA, which provides ingredients, equipment, and support to compounding pharmacies.
PCCA, Rapp says, will not sell peptides without legal standing more solid than enforcement discretion.
Samael Tejada also advises caution. Tejada runs the Liquivida wellness clinic in Hialeah, FL, and calls injectable therapies “the core of what we do.” He calls the potential of peptide therapy “real, but narrower than the headlines.” “It is not approval,” he says of the Oct. 28 declaration. “Any clinic marketing these as 'FDA-approved' is making a false claim.” Tejada’s prediction is that “cautious doctors will wait, and they are not wrong to,” and he also contends that careful adherence to documentation, safe suppliers, and consent will be essential.
Bob Baravarian is a California ankle surgeon and sells peptides via the Alpha Bioscience Labs brand he founded. His company “uses only US manufacturing and we perform third-party testing,” he says. The brand is physician-owned, boasts a physician board, and offers telehealth for best practices, and the enforcement-discretion policy now adds a layer of protection to the practice. “This approval process allows us to offer these peptides to our end user with a safe and effective process and less risk of scrutiny,” Baravarian says.
Many of the benefits of peptides shared online have been criticized as “bro science.” While online programs on peptide use have been developed to provide Continuing Medical Education credits and multiple associations offer practitioner credentials, state medical boards may not view peptides as well supported for the multitude of conditions consumers are seeking to treat with the drugs.
Fabricio Alves founded Plenivida Health as “a telehealth platform for women in midlife,” and says that clinics need to be clear with patients about the science, or the lack of it. “For all six, human evidence is thin, and operators should say so to patients,” Alves says.
Reverse Age Lab founder Robert DeuPree agrees, also using “thin” to describe the evidence. The peptides come with different levels of proof. He cites Semax as having the longest record of human use as an approved drug in Russia. Human trials are scarce for the other peptides. “Clinics that tell patients exactly where each peptide stands on human data will earn more trust than clinics that sell all six as proven,” DeuPree says. “Most published work on BPC-157, TB-500, epitalon, KPV, and MOTS-c is in animals or cells, with few controlled human trials.”
None of this means the peptides will not show up in longevity clinics. They already have. Doctors have been accused of guiding patients to websites that exploit a flimsy “research only” loophole that has not withstood enforcement action. In-clinic injections have been reported. The enforcement-discretion policy will undoubtedly convince more clinics that the lines have grown fuzzy enough that they can more safely enter the peptide space.
The patients who do knock on clinic doors looking for peptides will be the ones who are less comfortable with fuzzy lines, says Tejada, and they will be seeking the reassurance of professional care. The biohackers already using peptides who are comfortable ordering peptides cheaply online will continue to do so, he says. “The price-only buyers were never clinic patients. The risk is real at the margins. If a clinic's only offer is 'we can get you the vial,' it has no moat. Clinics that sell supervision, monitoring, and outcomes keep the patient. Clinics that sell access lose to a website.”
Michael James Hall is an MD at the Hall Longevity Clinic in Miami Beach. Hall says he sees peptides “as tools in a toolbox.” “Nobody asks whether a wrench is ‘good,’” Hall says. “They ask what it's being used to fix. In Infinite Youth, I describe aging as a funnel that narrows as load, signal, fuel, and capacity shift over time. So, I start by asking what's narrowing this person's funnel. It might be inflammation, weight, or cognitive function, and only then does a peptide enter the conversation. The evidence differs for each agent, and so does the right answer for each patient.”
Hall says he has experience with BPC-157, TB-500, epitalon, KPV, and Cerebrolysin. He believes the enforcement-discretion policy gives clinics an opportunity to provide better products matched with better care—and a chance to win customers open to long-term longevity therapy. “If all a clinic adds is a prescription and a markup, it deserves to lose that race.”
Alves sees the same dynamic in play. “The winner is whoever can document the whole chain: an FDA-registered source, a certificate of analysis, the prescriber, the pharmacy, and adverse-event reporting. Patients who choose on price alone were already buying ‘research use only’ vials.”
How MD-led longevity clinics approach peptides is likely to vary widely. Prescribing peptides remains illegal in a list of states that includes New York, California, and Connecticut. States like Alabama and Ohio are notable for taking action.
Hall says patients and doctors both need to be careful. “What concerns me most is patients mistaking access for proof. Add inconsistent product quality, poorly understood risks, and exaggerated promises, and you can do real harm while everyone feels very modern. Before changing practice, I'd also want state prescribing requirements and malpractice coverage checked.”
Brett Yonon has represented insurers as a trial attorney in Florida and says whatever practitioners do needs to be documented. That documentation needs to go past patients checking a box to indicate the risks have been explained. “If a patient is injured, I would look to see if the doctor documented lot numbers and doses,” Yonon says. “Even if the FDA decides not to act against a doctor for prescribing peptides, the doctor’s decision could still be reviewed (e.g., by a state medical board or jury) to determine whether the doctor should have prescribed the injections.”
The end result of this is that the enforcement discretion changes the peptide picture, but it doesn’t wipe the canvas clean. There are lines that still need to be followed, and coloring outside those lines can carry risk. When Alves and Tejada both talk about the opportunity being “narrow,” it may suggest how tightly those lines are being drawn.
Keep exploring LongevityBiz
Get the free weekly briefing on the science, companies, care models and capital shaping the longevity economy.
LongevityBiz Market Navigator™
Find and compare 300 companies across the longevity economy. Browse by category or ask a business question using everyday language.
More Deep Dives
Read more of Rick Polito’s original reporting on the people and business models shaping longevity care.
The free newsletter
Catch up on LongevityBiz market signals and earlier issues.
© 2026 The Longevity Biz, LLC.